JP2023513901A5 - - Google Patents

Info

Publication number
JP2023513901A5
JP2023513901A5 JP2022548978A JP2022548978A JP2023513901A5 JP 2023513901 A5 JP2023513901 A5 JP 2023513901A5 JP 2022548978 A JP2022548978 A JP 2022548978A JP 2022548978 A JP2022548978 A JP 2022548978A JP 2023513901 A5 JP2023513901 A5 JP 2023513901A5
Authority
JP
Japan
Prior art keywords
optionally substituted
deuterated
composition according
ester
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513901A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/017981 external-priority patent/WO2021163580A1/en
Publication of JP2023513901A publication Critical patent/JP2023513901A/ja
Publication of JP2023513901A5 publication Critical patent/JP2023513901A5/ja
Priority to JP2025202414A priority Critical patent/JP2026035680A/ja
Pending legal-status Critical Current

Links

JP2022548978A 2020-02-14 2021-02-12 タウオパチーの治療方法 Pending JP2023513901A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025202414A JP2026035680A (ja) 2020-02-14 2025-11-25 タウオパチーの治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976958P 2020-02-14 2020-02-14
US62/976,958 2020-02-14
PCT/US2021/017981 WO2021163580A1 (en) 2020-02-14 2021-02-12 Methods for treating tauopathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025202414A Division JP2026035680A (ja) 2020-02-14 2025-11-25 タウオパチーの治療方法

Publications (2)

Publication Number Publication Date
JP2023513901A JP2023513901A (ja) 2023-04-04
JP2023513901A5 true JP2023513901A5 (https=) 2024-02-20

Family

ID=77273602

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022548978A Pending JP2023513901A (ja) 2020-02-14 2021-02-12 タウオパチーの治療方法
JP2025202414A Pending JP2026035680A (ja) 2020-02-14 2025-11-25 タウオパチーの治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025202414A Pending JP2026035680A (ja) 2020-02-14 2025-11-25 タウオパチーの治療方法

Country Status (9)

Country Link
US (2) US20210251933A1 (https=)
EP (1) EP4103169A4 (https=)
JP (2) JP2023513901A (https=)
KR (1) KR20220140808A (https=)
CN (1) CN116507325A (https=)
AU (1) AU2021220981A1 (https=)
CA (1) CA3171330A1 (https=)
IL (1) IL295512A (https=)
WO (1) WO2021163580A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11510889B2 (en) 2021-02-05 2022-11-29 Retrotope, Inc. Methods for inhibiting the progression of neurodegenerative diseases
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
WO2022170134A2 (en) * 2021-02-05 2022-08-11 Retrotope, Inc. Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof
US11491130B2 (en) * 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
KR20240055796A (ko) * 2021-09-03 2024-04-29 바이오지바 엘엘씨 중수소화 pufa를 이용한 세포 기능장애 및 세포 사멸의 억제를 위한 방법, 시스템 및 조성물
IL313592A (en) * 2021-12-21 2024-08-01 Biojiva Llc Methods and preparations for the treatment of inflammatory disease
WO2023192406A2 (en) * 2022-03-30 2023-10-05 Retrotope, Inc. Prophylactic methods for treating als

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10052299B2 (en) * 2009-10-30 2018-08-21 Retrotope, Inc. Alleviating oxidative stress disorders with PUFA derivatives
JP6106157B2 (ja) * 2011-04-26 2017-03-29 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． 神経変性障害および筋疾患に関与するｐｕｆａ
WO2012148930A2 (en) * 2011-04-26 2012-11-01 Retrotope, Inc. Oxidative retinal diseases
CN110167546A (zh) * 2016-11-17 2019-08-23 乐巢拓普有限公司 同位素修饰的组分及其治疗用途
EP3461479B1 (en) * 2017-09-27 2021-06-16 Julie Blivet Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions
JP2021527648A (ja) * 2018-06-15 2021-10-14 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 後細胞シグナル伝達因子の調節による免疫活性の低減

Similar Documents

Publication Publication Date Title
JP2023513901A5 (https=)
AU2019226257B2 (en) Use of derivatives of polyunsaturated fatty acids as medicaments
CA2218699C (en) 1,3-propane diol derivatives as bioactive compounds
CA2607247C (en) .alpha.-substituted dha derivatives
RU2509071C2 (ru) Новые липидные соединения
WO2008053331A1 (en) Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar).
JP5552314B2 (ja) 新規脂質化合物
JP2015527386A5 (https=)
JP2019501135A5 (https=)
NZ596386A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
ES2401629B1 (es) Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
WO1998018751A1 (en) Presentation of bioactives
JP6784696B2 (ja) 硫黄を含有する構造的に強化された脂肪酸の非アルコール性脂肪性肝炎の予防及び／又は治療のための使用
JP2010509204A (ja) 脂肪酸アルコール
JP2016501248A5 (https=)
JP2018515463A5 (https=)
US20100267828A1 (en) dha derivatives and their use as medicaments
KR20180010181A (ko) Apo c3 의 저하를 위한 티아 옥소 화합물의 용도
US7649103B2 (en) Long chain unsaturated oxygenated compounds and their use in the therapeutical, cosmetic and nutraceutical field
JP2018510206A5 (https=)
JP2022504707A5 (https=)
WO2013037862A1 (fr) Phosphatidylcholines spécifiques en tant que modulateurs de l'activité du facteur d'activation plaquettaire
KR20180037915A (ko) 하이드록시-트리글리세라이드의 합성 방법 및 질병의 예방 및 치료에 사용되는 하이드록시-트리글리세라이드의 용도
CN1187813A (zh) 作为生物活性化合物的脂肪酸酯
RU2507193C2 (ru) Альфа-замещенные омега-3 липиды, которые являются активаторами или модуляторами рецептора, активируемого пролифераторами пероксисом (ppar)